KalVista Pharmaceuticals, Inc. (KALV)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $50.00M | — | — | — | — | — | $8.39M | $1.50M | $2.13M |
| Operating Income | -$188.00M | -$140.44M | -$110.87M | -$96.61M | -$57.92M | -$40.53M | -$29.82M | -$18.70M | -$22.34M | -$15.18M |
| Net Income | -$183.40M | -$126.60M | -$92.90M | -$82.34M | -$46.24M | -$29.12M | -$20.82M | -$15.80M | -$18.60M | -$11.44M |
| EPS (Diluted) | $-3.69 | $-3.44 | $-3.33 | $-3.36 | $-2.42 | $-1.64 | — | — | — | — |
| Total Assets | $335.38M | $235.40M | $183.20M | $203.88M | $272.01M | $92.53M | $118.13M | $61.39M | $34.34M | $24.75M |
| Total Liabilities | $338.09M | $28.82M | — | — | — | — | — | — | — | — |
| Shareholders' Equity | -$2.71M | $206.58M | $161.03M | $185.09M | $257.19M | $83.75M | $96.74M | $27.25M | $31.33M | -$37.11M |
| Cash & Equivalents | $229.34M | $31.79M | $56.24M | $30.73M | $50.59M | $15.79M | $32.01M | $51.05M | $30.95M | $21.76M |
| Operating Cash Flow | -$152.91M | -$89.23M | -$75.26M | -$78.13M | -$30.17M | -$44.82M | -$36.37M | $10.56M | -$23.72M | -$13.16M |
| Capital Expenditures | $434.0K | $42.0K | $1.20M | $931.0K | $82.0K | $220.0K | $1.08M | $1.43M | $74.0K | $11.0K |
| Shares Outstanding | 50.90M | 42.52M | 34.17M | 24.55M | 24.42M | 17.85M | 17.28M | 10.80M | 9.71M | 0 |